Finding the End of the Granulation Process - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Finding the End of the Granulation Process

Equipment and Processing Report

Untitled Document

Q: Our facility manufactures several products, and, from time to time, we must process ingredients that we haven’t encountered before through wet granulation. We try to use previous experience to develop the optimal granulation process for each new ingredient, but we sometimes get it wrong. Many times, we’ve taken materials from the granulator only to find that they exhibit poor flow and insufficient density. How can we easily determine the end point of a given granulation process?

A: One solution is to track wet granulation using a powder rheometer. Powder rheometers characterize samples by measuring them in motion. Basic flow energy (BFE), a dynamic powder parameter, can be a sensitive marker of the transition point from wet mass to granules and a precise tool for detecting when granules have attained their optimal properties.

BFE is the energy required to induce a specific flow pattern in a conditioned powder bed. One can measure BFE with a powder rheometer easily using wet samples taken directly from the granulator. Pause the granulation, extract a representative sample for measurement directly into the flow vessel of the powder rheometer, and continue processing if necessary.

To ensure a homogenous, representative sample, avoid the areas around the spray nozzle and walls, where material tends to be less uniform. Use large sample sizes for large granulates to ensure representative sampling of the batch. Automated measurement protocols can make the measurement fast and highly reproducible. The axial and rotational forces acting on a helical blade as it rotates through the sample are precisely measured to quantify the resistance of the bed (through BFE), which is governed by the properties of the wet granulate.

As water content increases, BFE climbs slowly, and it rises sharply at concentrations coincident with the end point. Physical examination of the samples suggests that this sharp rise corresponds with the transition from wet mass to granules.

Because BFE is independent of scale, it is of great value when switching from laboratory to pilot to commercial scale. Processing to an endpoint defined in this way gives the operator scope to vary conditions in response to changing feed, scale, or equipment. The approach also is consistent with quality by design.

—Tim Freeman, director of operations for Freeman Technology


If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here